Prognostic significance of bone marrow fibrosis in diffuse large B‐cell lymphoma
International Journal of Laboratory Hematology · 2024-06 · 46 (3) · 523-530
DOI: 10.1111/ijlh.14249 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, online erschienen am 15.02.2024. Verfasst von Tugba Cetintepe und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Bone Marrow. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin lymphomas. The aim of this study is to determine the relationship between the increase in the degree of fibrosis in the bone marrow and prognosis and mortality in newly diagnosed DLBCL.
Methods
Bone marrow biopsy of 153 newly diagnosed DLBCL patients was determined by staining with reticulin, Masson's trichrome histochemical stain, and the degree of fibrosis was determined.
Results
In the bone marrow biopsy performed at the time of diagnosis, bone marrow fibrosis (BMF) was observed in 70 patients. While BMF‐1 was detected in 42 patients (60%), BMF‐2 was detected in 25 patients (35%) and BMF‐3 was detected in 3 patients (4%). As the degree of BMF increased, the median overall survival and median progression‐free survival times were significantly shorter ( p : 0.008), ( p < 0.001). In patients with an increased degree of BMF, a significant decrease in leukocyte and neutrophil counts was observed after chemotherapy ( p : 0.004). According to the results of the multivariate Cox regression model, it was determined that high NCCN‐IPI risk (HR: 8.25; %95 CI: 1.09–62.52; p = 0.041) and being BMF ≥ 2 (HR: 3.75; %95 CI: 1.65–8.51; p = 0.002), increased the risk of death ( p = 0.002, −2 loglikelihood = 392,553).
Conclusion
When the literature was reviewed, it was seen that this study was the first to define that bone marrow fibrosis grade 2 and above in DLBCL is a prognostic marker associated with worse survival. In the bone marrow pathology, which is examined to detect advanced disease in DLBCL, besides lymphomatous involvement, the detection of fibrosis grade is very important.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey.
- Department of Internal Medicine, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey.
- Department of Pathology, Izmir Katip Celebi University, Ataturk Training and Research Hospital, Izmir, Turkey.
- Department of Nephrology, Karaburun State Hospital, Izmir, Turkey.
ORCID-Profile: Tugba Cetintepe, Gamze Ozkan, Betul Polat Kucukzeybek, Lutfi Cetintepe, Demet Kiper Unal, Serife Solmaz, Kemal Aygun, Alev Garip Acar, Sadi Bener, Aylin Orgen Çallı, Kadriye Bahriye Payzın
Zitieren
APA
Cetintepe, T., Ozkan, G., Kucukzeybek, B. P., Cetintepe, L., Unal, D. K., Solmaz, S., Aygun, K., Acar, A. G., Bener, S., Çallı, A. O., & Payzın, K. B. (2024). Prognostic significance of bone marrow fibrosis in diffuse large B‐cell lymphoma. International Journal of Laboratory Hematology, 46(3), 523-530. https://doi.org/10.1111/ijlh.14249
Vancouver
Cetintepe T, Ozkan G, Kucukzeybek BP, Cetintepe L, Unal DK, Solmaz S, et al. Prognostic significance of bone marrow fibrosis in diffuse large B‐cell lymphoma. International Journal of Laboratory Hematology. 2024;46(3):523-530. doi:10.1111/ijlh.14249
BibTeX
@article{Cetintepe2024,
author = {Cetintepe, Tugba and Ozkan, Gamze and Kucukzeybek, Betul Polat and Cetintepe, Lutfi and Unal, Demet Kiper and Solmaz, Serife and Aygun, Kemal and Acar, Alev Garip and Bener, Sadi and Çallı, Aylin Orgen and Payzın, Kadriye Bahriye},
title = {Prognostic significance of bone marrow fibrosis in diffuse large B‐cell lymphoma},
journal = {International Journal of Laboratory Hematology},
year = {2024},
volume = {46},
number = {3},
pages = {523--530},
doi = {10.1111/ijlh.14249}
}
EUVIMED